Filing Details
- Accession Number:
- 0001209191-17-056469
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-10-10 16:35:43
- Reporting Period:
- 2017-10-10
- Accepted Time:
- 2017-10-10 16:35:43
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1649904 | Rhythm Pharmaceuticals Inc. | RYTM | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1237289 | D Scott Sandell | 1954 Greenspring Drive Suite 600 Timonium MD 21093 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-10-10 | 1,402,870 | $0.00 | 1,432,248 | No | 4 | C | Indirect | See Note 2 |
Common Stock | Acquisiton | 2017-10-10 | 2,927,708 | $0.00 | 4,359,956 | No | 4 | C | Indirect | See Note 2 |
Common Stock | Acquisiton | 2017-10-10 | 550,000 | $17.00 | 4,909,956 | No | 4 | P | Indirect | See Note 2 |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Note 2 |
No | 4 | C | Indirect | See Note 2 |
No | 4 | P | Indirect | See Note 2 |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A Preferred Stoc | Disposition | 2017-10-10 | 1,402,870 | $0.00 | 1,402,870 | $0.00 |
Common Stock | Series A-1 Junior Preferred Stock | Disposition | 2017-10-10 | 2,927,708 | $0.00 | 2,927,708 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") and series A-1 junior preferred stock (the "Series A-1 Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred and the Series A-1 Preferred had no expiration date.
- The Reporting Person is a director of NEA 13 GP, LTD, which is the sole general partner of NEA Partners 13, L.P. ("NEA Partners 13"). NEA Partners 13 is the sole general partner of New Enterprise Associates 13, L.P. ("NEA 13"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 shares in which the Reporting Person has no pecuniary interest.
- Reflects the number of shares of Series A Preferred and Series A-1 Preferred, as applicable, held by the Reporting Person on an as-converted to common stock basis.